Cytek Biosciences, Inc. (CTKB) Stock Analysis

Cytek Biosciences’ principal competitive advantage is its proprietary Full Spectrum Profiling (FSP) technology, which enables higher-parameter, more sensitive cell analysis than conventional flow cytometry. Unlike traditional systems that detect a limited range of fluorescent signals, Cytek’s FSP instruments (notably the Aurora and Northern Lights families) capture the entire emission spectrum, allowing for the simultaneous measurement of up to 50 biomarkers per sample. This capability is particularly valued by advanced research and clinical labs seeking deeper biological insights and workflow efficiency.

Cytek’s installed base is growing at a double-digit rate, with over 3,900 instruments placed globally as of mid-2026. This expanding footprint underpins a high-margin, recurring revenue stream from reagents and service contracts—recurring revenue now accounts for 35% of total sales, up from 32% a year ago. Customer satisfaction is reinforced by robust application support, intuitive software (Cytek Cloud), and rapid reagent delivery.

Compared to entrenched rivals such as Becton Dickinson (BD), Beckman Coulter (Danaher), and Thermo Fisher, Cytek lacks scale and brand incumbency but differentiates on technical performance and flexibility. While BD and Thermo Fisher benefit from vast installed bases and deep customer relationships, Cytek’s technology is increasingly seen as the new industry standard for high-parameter analysis, with peer-reviewed publications and key opinion leader endorsements accelerating adoption. However, the company remains exposed to competitive responses, pricing pressure, and the risk of customer inertia in switching from legacy platforms.